In Costly Cancer Drug, Hope and a Dilemma: Some Pay Up to $100,000 a Year for Avastin's Arguable Benefits

Author

Kolata, Gina

Pollack, Andrew

Bibliographic Citation

New York Times 2008 July 6; p. A1, A16, A17

Permanent Link

Find in a Library
http://hdl.handle.net/10822/956184

Date

2008-07-06

Subject

Cancer; Social Control of Science and Technology; Allocation of Health Care Resources; Drugs and Drug Industry; Economics of Health Care; Health Care for Particular Diseases or Groups;

Collections

EthxWeb: Literature in Bioethics

Metadata

Show full item record